Dear Editor:I read with great interest the recent article by Stephen et al.(For instance, in a recent study, intranasal sufentanil was rated as a better alternative than prestudy breakthrough medication in 77 percent of patients with cancer. (1) Intranasal sufentanil is rapidly emerging as a treatment alternative in a number of other scenarios besides its role in achieving effective pain control in the emergency department. Intranasal administration is safe and provides rapid relief in patients with cancer who experience breakthrough cancer pain. The low prevalence of systemic side effects makes it an ideal option in patients with cancer.2)Read more...